Consensus guidance clarifies IV ketamine dosing, monitoring, staffing and consent to support safer, evidence-based depression treatment.
Sandhya Prashad, MD
Advertisement
Articles by Sandhya Prashad, MD
New Delphi consensus guides off-label IV ketamine for depression, detailing protocols and rapid antisuicidal mechanisms via neuroplasticity and BDNF.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
New 6-Month Data From Second Phase 3 Trial Confirms Rapid Effect of COMP360 for TRD
2
Take-Home Messages: Clinical Confidence in Transitioning Patients to Cobenfy
3
Developments in Cannabis Withdrawal and Addiction Treatment
4
Phase 2 Trial Initiated for Briumvi for Treatment-Resistant Schizophrenia
5